Guidance: Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
FDA issued final guidance on washout periods and concomitant medications in cancer clinical trial eligibility criteria, affecting trial design and patient enrollment. No direct impact on manufacturing or drug approval processes.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: None. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA clarified recommendations for washout periods and concomitant medication use in cancer trial eligibility criteria.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Review guidance to ensure clinical trial protocols align with updated recommendations; no immediate compliance action required.
Deadline
None
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Section 301 Action: Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure of Each Economy to Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced with Forced Labor
- Guidance: Cancer Clinical Trial Eligibility Criteria: Performance Status
- DOJ Moves FDA Approved and Medical Marijuana to Schedule III - ArentFox Schiff
- FDA Proposes to Eliminate "Adequate Provision" for Broadcast Prescription Drug Advertising - Foley Hoag
- US-CONGRESS S5004: Cancer Drug Parity Act of 2026